BLACK DIAMOND THERAPEUTICS, INC. Weighted Average Number of Shares Outstanding, Basic and Diluted
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 32.91 million shares for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-25.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2021-03-25
- BLACK DIAMOND THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-12-31 was 36.05M shares, a 1583.88% increase year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-09-30 was 35.93M shares, a 1639.26% increase year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-06-30 was 35.91M shares, a 1649.99% increase year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-03-31 was 23.70M shares, a 1059.24% increase year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 32.91M shares, a 1485.31% increase from fiscal 2019.
- BLACK DIAMOND THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2019 was 2.08M shares, a 2.83% increase from fiscal 2018.
- BLACK DIAMOND THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2018 was 2.02M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2020-12-31 | 36.05M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | 35.99M shares derived: average of 2 quarters · filed 2021-03-25 | 35.96M shares derived: average of 3 quarters · filed 2021-03-25 | 32.91M shares 10-K · filed 2021-03-25 |
| 2020-09-30 | 35.93M shares 10-Q · filed 2020-11-10 | 35.92M shares derived: average of 2 quarters · filed 2020-11-10 | 31.86M shares 10-Q · filed 2020-11-10 | 24.42M shares derived: average of 4 quarters · filed 2021-03-25 |
| 2020-06-30 | 35.91M shares 10-Q · filed 2020-08-11 | 29.80M shares 10-Q · filed 2020-08-11 | 20.58M shares derived: average of 3 quarters · filed 2021-03-25 | 15.95M shares derived: average of 4 quarters · filed 2021-03-25 |
| 2020-03-31 | 23.70M shares 10-Q · filed 2020-05-12 | 12.92M shares derived: average of 2 quarters · filed 2021-03-25 | 9.30M shares derived: average of 3 quarters · filed 2021-03-25 | 7.49M shares derived: average of 4 quarters · filed 2021-03-25 |
| 2019-12-31 | 2.14M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | 2.10M shares derived: average of 2 quarters · filed 2021-03-25 | 2.09M shares derived: average of 3 quarters · filed 2021-03-25 | 2.08M shares 10-K · filed 2021-03-25 |
| 2019-09-30 | 2.07M shares 10-Q · filed 2020-11-10 | 2.06M shares derived: average of 2 quarters · filed 2020-11-10 | 2.05M shares 10-Q · filed 2020-11-10 | |
| 2019-06-30 | 2.05M shares 10-Q · filed 2020-08-11 | 2.05M shares 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | 2.04M shares 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | 2.02M shares 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |